c-Kit tyrosine kinase receptor and its ligand stem cell factor have multiple functions during development, whereas in adulthood they are mostly needed for stem cell (SC) maintenance and mast cell (MC) biology. c-Kit plays an essential tumor-cell-intrinsic role in many types of cancer, either providing the tumorigenic force when aberrantly activated or conferring stem-like features characterizing the most aggressive variants. A tumorcell-extrinsic role occurs through c-Kit-dependent accessory cells (such as MCs) that infiltrate tumors and deeply influence their progression. c-Kit-targeted therapy with tyrosine kinase inhibitors (TKIs) may ideally work against both tumor and stromal cells. Here, we summarize the tumor-intrinsic and -extrinsic roles of c-Kit in cancer and discuss TKIs with their on-and off-targets, with a special emphasis on MCs as paradigmatic c-Kit-dependent accomplices for tumor progression.
Introduction c-Kit (CD117) is a tyrosine kinase (TK) receptor of the class III subfamily, which also includes the receptor for platelet-derived growth factor (PDGFR), the receptor for macrophage colony-stimulating factor-1 and FMSlike TK 3. Kit was originally described in its viral form (v-Kit), as the oncogene responsible for the transforming activity of the Hardy-Zuckerman IV feline sarcoma virus (Besmer et al., 1986) , whereas its human protein counterpart was first identified as a cell-surface marker of human acute myeloid leukemia cells (Gadd and Ashman, 1985) . Nonetheless, the strongest evidence of the crucial role in physiology of c-Kit receptor and its ligand stem cell factor (SCF), also known as Kit ligand, steel factor and mast cell growth factor, came from the mapping of these two molecules to the White spotting (W) (Chabot et al., 1988; Geissler et al., 1988) and Steel (Sl) loci, respectively. Mice with spontaneous mutations at either W or Sl locus display indeed a very similar and pleiotropic phenotype, including severe macrocytic anemia, mast cell (MC) deficiency, sterility and pigmentation defects (Silvers, 1979) .
Since then, the SCF/c-Kit axis has been extensively studied and many reports have contributed to elucidate its essential role in haematopoiesis, melanogenesis and gametogenesis, but have also extended its extreme biological relevance to the fields of stem cells (SCs) and cancer cell biology. Among the c-Kit-dependent cells, interest is renewed for MCs that, beyond classical histamine-releasing cells in allergic reactions, are now viewed as multifunctional and plastic cells intervening in a variety of reactions, such as protection from pathogens, autoimmune and inflammatory disorders, transplantation tolerance, metabolic diseases, and, most importantly, cancer progression (Kinet, 2007; Galli et al., 2008; Beaven, 2009 ). This review focuses on the SCF/c-Kit axis in physiological and pathological conditions, especially cancer. Tumor-cell-intrinsic and -extrinsic roles of c-Kit are discussed, with emphasis on MCs, accomplices for tumor progression that, strongly relying on c-Kit, represent the primary off-target of c-Kit-directed cancer therapy.
Biology of the SCF/c-Kit axis
Expression of c-KIT and SCF As a member of the PDGFR family, c-Kit receptor is characterized by an extracellular ligand-binding region containing five immunoglobulin-like repeats, a transmembrane sequence, an autoinhibitory juxtamembrane domain and two intracellular TK domains: an ATPbinding pocket and a kinase activation loop (Liu et al., 2007) (Figure 1 ). SCF is produced as a glycosylated transmembrane protein. Alternative splicing originates two isoforms, one containing a cleavage site, leading to its proteolysis and release as a soluble homodimer, and the other remaining cell associated (Anderson et al., 1991) .
During embryonic life, c-Kit and SCF are expressed along the migratory pathways and in the homing locations of primordial germ cells and melanocytes, in sites of haematopoiesis, in the gut and central nervous system (Matsui et al., 1990; Orr-Urtreger et al., 1990) , suggesting that the SCF/c-Kit axis is crucial to guide cells to their ultimate destinations during development.
In the adult, c-Kit and SCF are required for the maintenance of normal basal haematopoiesis, with c-Kit expressed by haematopoietic SCs and progenitors along all the haematopoietic cells hierarchy and on B-and T-lymphocyte precursors, and SCF constitutively produced by stromal cells, fibroblasts and endothelial cells of primary and secondary lymphoid organs (Broudy, 1997) . Similarly, the SCF/c-Kit signaling pathway is pivotal for the maintenance of bone marrow mesenchymal SCs (Majumdar et al., 2000) and of adult SCs in compartments other than the bone marrow, such as liver (Laurson et al., 2007) , heart (Zaruba et al., 2010) and prostate (Leong et al., 2008) . c-Kit and SCF are also found in the adult gonads (Hutt et al., 2006) . In general, c-Kit expression is a common trait of stem and precursor cells in the organism, suggesting that signaling through the SCF/c-Kit axis may be key in conferring and maintaining stemness.
c-Kit expression is usually downregulated upon terminal differentiation; however, there are some cells that retain a high c-Kit reliance even at their final stage of differentiation and are indeed mostly affected by even mild W mutations: MCs, melanocytes and the interstitial cells of Cajal (ICCs), intestinal cells with pacemaker activity. In particular, MCs express high levels of c-Kit and are strongly SCF-dependent (Galli et al., 1993) , not only for their development, but also for their survival (Moller et al., 2005) , migration (Meininger et al., 1992) and activation (Taylor et al., 1995; Okayama and Kawakami, 2006; Gilfillan and Rivera, 2009 ).
SCF/c-KIT signaling SCF binding to c-Kit induces a conformational change, resulting in the dimerization of the receptor, followed by the activation of its intrinsic TK activity. The activated receptor becomes autophosphorylated on key tyrosine residues, which serve as docking sites for signal transduction molecules containing Src homology 2 or phosphotyrosine-binding domains (Ronnstrand, 2004) . Multiple downstream signaling pathways can thus be activated, including the Ras/ERK, phosphatidylinositol 3-kinase (PI3-K), Src kinases and JAK/STAT pathways, and very diverse biological responses elicited, according to the state and type of the responding cell (Young et al., 2007) . In MCs, c-Kit signaling hinges specifically on K-Ras pathways (Khalaf et al., 2007) , inducing a cascade ultimately activating p44/p42 (ERK1/2), p38 and AKT. Specifically, it seems that the Raf-MEK-ERK pathway primarily modulates proliferation and cytokine synthesis, the PI3K-Rac2-Pak-p38 pathway modulates F-actin rearrangement and cellular motility, and AKT Figure 1 c-Kit structure and mutations found in human malignancies and experimental mouse models. The structure of c-Kit receptor is characterized by an extracellular ligand-binding region containing five immunoglobulin-like repeats (encoded by exon 9 of the Kit gene), a transmembrane sequence, an autoinhibitory juxtamembrane domain (exon 11) and two intracellular TK domains: an ATPbinding pocket (exon 13 and 14) and a kinase activation loop (exon 17) (Liu et al., 2007) . Mutations in c-Kit extracellular region are found in about 9% of GIST patients and are sensitive to imatinib. Mutations in the juxtamembrane domain are found in most (70%) GIST patients and are sensitive to imatinib; the experimental model for mutations at this site is the c-Kit 558delV transgenic mouse, which develops GIST and SM (Sommer et al., 2003) . Mutations in c-Kit TK domains are typical of SM, or occur in GIST patients as secondary mutations conferring resistance to imatinib. Some second generation TKIs have proven to be effective in inhibiting c-Kit isoforms affected by these mutations. The transgenic mouse expressing the D816V c-Kit mutant under the MC-specific chymase gene promoter spontaneously generates SM, similar to the human counterpart (Zappulla et al., 2005) . Other mouse models of c-Kit mutated at this site are the K641E transgenic (characterized by GIST and MC deficiency) (Rubin et al., 2005) , D818Y transgenic (developing GIST) (Nakai et al., 2008) and MC-deficient mouse W-v (Nocka et al., 1989) .
c-Kit and mast cells in cancer P Pittoni et al activation modulates the Bcl-2 family of proteins to prevent apoptosis, increasing MC survival Staser et al., 2010) . Binding of SCF to c-Kit on MCs also induces JAK2 activation, which results in phosphorylation of several STATs, including STAT1a, STAT3, STAT5 and STAT6. In particular, STAT5 contributes to MC homeostasis by supporting proliferation, survival and mediator release (Morales et al., 2010) . c-Kit signal transduction can be shut off through a variety of mechanisms. As other TK receptors, c-Kit is monoubiquitinated upon ligand stimulation, then internalized and degraded in the lysosomes. Moreover, the contribution of different molecules to the downmodulation of c-Kit signaling, including PKC, SOCS-1 and SHP-1 (Ronnstrand, 2004) , has been described. Among them, we should mention neurofibromin, a protein encoded by the tumor suppressor gene Nf1, whose mutations are at the basis of the genetic disease neurofibromatosis type 1 (NF1) (Staser et al., 2010) . Neurofibromin potentiates the hydrolysis of Ras-guanosine triphosphate to Ras-guanosine diphosphate, its inactive form, thus functioning as a negative regulator of Ras-dependent pathways. The importance of neurofibromin in SCF/c-Kit signaling is demonstrated by the evidence that MCs and melanocytes bearing half or null dose of Nf1 display a hyperactive c-Kit-mediated response to SCF (Ingram et al., 2000) .
The SCF/c-Kit axis induces the expression of a number of genes. One of these is Slug (Perez-Losada et al., 2002), a member of the Snail family of zinc finger transcription factors, which is involved in epithelialmesenchymal transition during embryonic development and cancer progression. Slug-deficient mice have indeed a cell-intrinsic defect with pigment deficiency, gonadal defect and impairment of haematopoiesis, a phenotype that is reminiscent of that of c-Kit mutant mice. MC development appears normal in these mice (Perez-Losada et al., 2002) , suggesting, once again, that the cellular context dictates the outcome of the SCF/c-Kit signal.
Roles of c-Kit in tumor cells
Since its identification in the 1980s, c-Kit has been considered as a proto-oncogene, due to the strict connection existing between alterations in its expression/activity and cancer development. Here, c-Kitexpressing tumors are classified into two main groups: those in which c-Kit activation plays a central pathogenetic role in the initiation of the neoplasm and those in which c-Kit has no substantial role in tumor initiation but is rather acquired upon tumor progression.
Tumors of c-Kit expressing cells
Tumors of the first group are derived from the transformation of cells that normally express c-Kit, and are usually characterized by gain-of-function c-Kit mutations (detailed below and summarized in Figure 1 ), conferring constitutive ligand-independent phosphorylation and downstream activation. In these tumors, c-Kit aberrant activation is the fundamental molecular event determining their development. We can include to this group gastrointestinal stromal tumors (GISTs) (Liegl-Atzwanger et al., 2010) , mastocytosis (Swerdlow et al., 2008) , germ cell tumors (Izquierdo et al., 1995; Kemmer et al., 2004) , Kit-driven acute myeloid leukemia (Ikeda et al., 1991; Paschka et al., 2006) and Kitdriven melanomas (Curtin et al., 2005) . The description of some of these neoplasms exemplifies the role of c-Kit in their pathogenesis.
Gastrointestinal stromal tumors. GISTs are mesenchymal tumors of the gastro-intestinal tract. They are most common in stomach and small intestine, and comprise a spectrum of lesions from benign to malignant. Before the late 1990s, they were classified as smooth muscle tumors or neural tumors, whereas only recently, they have been recognized as a separate entity, originating from the oncogenic transformation of ICCs (Kindblom et al., 1998) . ICCs are dendritic-shaped, mesenchymal spindle cells located in the muscularis propria and around the myenteric plexus throughout the gut, whose function is to orchestrate the peristaltic activity by working as the pacemaker of the intestinal muscle layers. ICCs are characterized by high-c-Kit expression, which is necessary for their postnatal development and proliferation (Maeda et al., 1992) . GISTs are indeed strongly c-Kit positive and 60-70% of them have c-Kitactivating mutations, mostly deletions or insertions (Liegl-Atzwanger et al., 2010) . Another 5-10% display mutations in the Pdgfra gene. Most c-Kit mutations (o65%) involve its juxtamembrane domain (exon 11) and impair its autoinhibitory functions; other common mutations involve the extracellular dimerization domain (exon 9) and induce ligand-independent receptor dimerization (Corless and Heinrich, 2008) (Figure 1 ). Most GISTs are sporadic, but familial forms with germline c-Kit mutations have been described.
Mastocytosis. Mastocytosis is a heterogeneous group of clinical disorders characterized by the neoplastic proliferation of MCs that accumulate in various tissues (WHO classification, Swerdlow et al., 2008) . In cutaneous mastocytosis, MCs accumulate in the skin; an indolent course is pursued when the disease remains confined to isolated cutaneous localization. Conversely, in systemic mastocytosis (SM), malignant MC infiltration affects the bone marrow and, variably, other extracutaneous organs, such as liver, spleen and peripheral blood. Both indolent and aggressive forms of SM have been described, with leukemic presentations showing the worst outcome. It is now accepted that the clonal proliferation of MCs is driven by a c-Kit activating mutation (Bodemer et al., 2010) consisting, in most cases, in a valine for aspartic acid substitution (D816V) in the catalytic domain ( Figure 1 ). The remarkable coexistence of SM and other non-MC hematological neoplasms (Fritsche-Polanz et al., 2010) suggests a disturbed homeostatic regulation of the haematopoietic SC pool, which may be related to the underlying c-Kit mutation.
c-Kit and mast cells in cancer P Pittoni et al Melanoma. c-Kit is essential for melanogenesis, as demonstrated by the pigmentation defects of mice and humans with loss-of-function mutations in c-Kit (Silvers, 1979; Winship et al., 1991) . However, past works, showing that c-Kit expression is usually lost in melanomas (Lassam and Bickford, 1992) and that its restoration in metastatic melanoma cells even results in tumor apoptosis (Huang et al., 1996) , pointed to the idea that c-Kit did not play a role in promoting melanomas. This notion held as long as recent seminal findings showed that a subgroup of melanomas, in particular those from acral lentiginous, mucosal and chronic sun-damaged sites, frequently harbor point-activating mutations and/or increased copy number of the Kit gene (Curtin et al., 2005) .
Neurofibromatosis. One more tumor condition could be numbered among this first group of tumors, due to its strict dependence on c-Kit abnormal activation: NF1. NF1 is a common genetic disorder characterized by mutations in Nf1 gene, which predispose affected individuals to a variety of disorders, mainly caused by Nf1 loss of heterozygosity in different cell lineages. As previously mentioned, the product of Nf1 gene, neurofibromin, is a negative regulator of Ras; therefore, its loss results in the aberrant activation of multiple cellular pathways, including c-Kit signaling. The hallmark of NF1 patients is the formation of cutaneous, diffuse and plexiform neurofibromas, tumors originating from Schwann cells, but also composed of blood vessels, fibroblasts and MCs. Experiments with NF1 conditional knockout mice have pointed out that Nf1 loss of heterozygosity in Schwann cells is necessary, but not sufficient to elicit neurofibromas (Zhu et al., 2002) and that Nf1 haploinsufficiency in MCs, which appear in peripheral nerves much before tumor development, is also required (Yang et al., 2008) . Interestingly, in this condition, NF1 aberrations act at two levels: NF1 null Schwann cells have been shown to secrete very high concentrations of SCF (Yang et al., 2003) , attracting MCs, and NF1 heterozygous MCs display a hyperactive c-Kit-mediated response to SCF (Ingram et al., 2000) , thus promoting tumor growth. Therefore, in the peculiar case of NF1, cKit is expressed in its native form, but mutations in a molecule other than c-Kit (NF1) lead to a hyperactivation of its downstream signaling, which ultimately results in tumor formation.
It is worth mentioning that multiple manifestations involving different cell lineages in individuals with pathologic c-Kit activation are not uncommon, such as cutaneous hyperpigmentation (Maeyama et al., 2001) or mastocytosis (Robson et al., 2004) in patients with familial GISTs, GISTs in NF1 patients (Hirashima et al., 2009) or mastocytosis in patients with germ cell tumors (Teitell and Rowland, 1998) .
Tumors acquiring c-Kit upon progression
The second group of c-Kit-expressing tumors comprises neoplasms derived from cells that normally do not express c-Kit. Belong to this group cases of small cell lung cancer (Krystal et al., 1996) , adenoid cystic carcinoma (Freier et al., 2005) , colon carcinoma (Bellone et al., 2006) , and brain tumors (Gomes et al., 2007) . c-Kit mutations are rare in these neoplasms, but in several cases autocrine loops have been described, in which tumors are able to provide c-Kit stimulation by producing SCF themselves (Stanulla et al., 1995; Krystal et al., 1996; Bellone et al., 2006) . Breast cancer. Peculiar and emblematic is the case of breast cancer: c-Kit is weakly expressed by normal breast ductal epithelia (Yared et al., 2004) and is usually lost upon transformation, so that the majority of breast tumors are c-Kit negative (Natali et al., 1992; Ko et al., 2003) . Interestingly, though, c-Kit positivity is found in breast carcinomas with basal/myoepithelial cell differentiation, a subset of high-grade, prognostically unfavorable tumors, lacking hormone and epidermal growth factor receptors (so called 'triple negative' carcinomas) (Palmu et al., 2002) . Interpreting this finding, we can speculate that the gain of c-Kit correlates with progression of tumors to a more malignant and undifferentiated stage, characterized by SC features (Tsuda et al., 2005) , such as c-Kit reliance. Accordingly, c-Kit expression has been associated to a bad clinical outcome in colorectal cancer (Bellone et al., 2006) . Moreover, Slug, a known downstream target of the c-Kit pathway, is a key transcription factor orchestrating epithelial-mesenchymal transition, the process defined by the loss of epithelial markers and the acquisition of a mesenchymal phenotype, typical of tumors with high aggressiveness and metastatic potential. Expression of c-Kit and Slug correlates indeed with invasion and metastasis in salivary adenoid cystic carcinoma (Tang et al., 2010) . Identification of selfrenewing, stem-like cells within tumors, named cancer stem cells, has indicated the crucial cell to be targeted in cancer therapy. Markers of epithelial-mesenchymal transition are highly expressed in cancer stem cells, suggesting that cancer stem cells may arise from differentiated-tumor cells that acquire SC-like properties as a consequence of epithelial-mesenchymal transition (Mani et al., 2008) . In this context, c-Kit may be one of the relevant signaling pathways maintaining the cancer stem cell pool in tumors.
Roles of MCs in cancer development
The role of c-Kit in cancer is not limited to tumor-cellautonomous functions. Indeed, c-Kit ablation in nontumor cells has been proven to influence tumor growth in a variety of experimental models (reviewed by Maltby et al., 2009) . MCs, which mostly rely on c-Kit/SCF axis for development, migration and activation, are currently believed to contribute significantly to tumor progression. Since the first observation of MCs surrounding tumor foci, dating back to 1891 (Westphal, 1891) , many reports have confirmed MC attraction to tumor beds and highlighted the multiple functions operated by MCs in fostering angiogenesis, tissue remodeling and immune modulation in human and murine cancer (Maltby et al., 2009) . MCs may exert pro-or anti-tumor functions, depending on tumor type/stage, on microenvironmental c-Kit and mast cells in cancer P Pittoni et al signals and neighboring interacting cells (Theoharides and Conti, 2004) . Such MC functional complexity may explain the discrepancy emerging from different studies, showing opposite correlations of MC accumulation with prognosis in different settings (Maltby et al., 2009) . Here, MC activities will be subdivided into two main groups, according to their predominant involvement as stromal cell components or immunological regulators.
Roles in angiogenesis and invasinevess
MCs have been shown to positively impact stroma remodeling and tumor angiogenesis through several mechanisms (Crivellato et al., 2008) , thus supplying the nourishment to tumor cells as reminisced by their original name 'mastzellen' (from the Greek 'masto,' meaning 'to feed') (Theoharides, 2008) . A seminal work by Coussens and et al. (1999) revealed early infiltration of MCs promoting neoangiogenesis in hyperplastic lesions in a mouse model of skin squamous carcinogenesis. MC-specific proteases promote the proliferation of stromal fibroblasts and the release of active MMP-9, a proteinase mostly provided by inflammatory cells in the tumor microenvironment, which plays pivotal roles in extracellular matrix remodeling and tumor invasiveness (Coussens et al., 2000) . MMP-9 is crucially involved in the mobilization from the extracellular matrix of bioactive vascular endothelial growth factor (VEGF), which drives the switch from vascular quiescence to neoangiogenesis (Bergers et al., 2000; Melani et al., 2007) . The physiological role of MMP-9 in the c-Kit/SCF axis, regulating the availability of soluble SCF necessary for mobilization of SCs in the bone marrow niche (Heissig et al., 2002) , may degenerate to a vicious circle in the tumor milieu. Indeed, MC-derived MMP-9 cleaves membrane-bound SCF from the tumor cell surface, which in turn further amplifies MC attraction and activates an immunosuppressive program in MCs (Huang et al., 2008) . In a plasmacytoma mouse model, MC-derived angiopoietin-1 has been shown to cooperate with tumor-cell-derived VEGF in inducing neovascularization (Nakayama et al., 2004) . Adrenomedullin, a peptide amide released in hypoxic milieus and abundant in many malignancies, mediates a bidirectional cross-talk between tumor cells and MCs: tumorderived adrenomedullin promotes chemotaxis, histamine degranulation and release of proangiogenic factors by MCs, whereas MC-derived adrenomedullin directly promotes neoangiogenesis (Zudaire et al., 2006) . In a rat model of prostate cancer, peritumoral MCs show expression of FGF2, a molecule endowed with well-known proangiogenic roles . Very early upon activation of the Myc oncogene in a mouse model of inducible insulinoma, transforming cells secrete inflammatory chemokines that rapidly recruit MCs to islet stroma (Soucek et al., 2007) . Pharmacological (via the MC degranulation stabilizer Cromolyn) or genetic (by using c-Kit mutant mice) MC blockade severely dampens the extensive vascular assembly that is necessary for advanced expansion of transformed foci, a finding clearly demonstrating the causal relationship between tumorassociated MCs and angiogenesis (Soucek et al., 2007) .
Immune and inflammatory roles
There is a growing acceptance that a chronically inflamed microenvironment, rich in proangiogenic and mitogenic cytokines, fosters tumor initiation and progression (Mantovani et al., 2008) . Through the secretion of cytokines, such as tumor necrosis factor-a (TNF-a) and interleukin (IL)-6, MCs may directly contribute to the establishment of an inflammatory milieu. In polypprone mice, pharmacological TNF-a neutralization or genetic MC ablation significantly reduce polyp outgrowth (Gounaris et al., 2007) . MC activation through c-Kit drives an inflammatory transcriptional program encompassing IL-6, TNF-a, VEGF, Cox-2, iNOS and CCL2 (Huang et al., 2008) . Also, in a mouse hepatocarcinoma model, SCF-activated MCs promote the intratumor accumulation of IL-17 (Huang et al., 2008) , a proinflammatory cytokine that may play complex, and still controversial, roles in tumor progression (MartinOrozco and Dong, 2009).
Immunosuppression that constantly characterizes the tumor microenvironment is an important aspect of tumor-induced escape from immune surveillance. MCs may directly express immunomodulatory molecules and/or orchestrate interactions with other regulatory cell populations (reviewed by Wasiuk et al., 2009) . SCFactivated MCs secrete adenosine, which directly inhibits T-and natural killer cell activation (Huang et al., 2008) . MCs may also secrete the suppressive cytokines IL-10 and TGF-b, thus directly exerting immunoregulatory functions at tumor sites, as already described in other contexts, such as the mouse skin during contact hypersensitivity reactions (Grimbaldeston et al., 2007) and the human gut during chronic phases of inflammatory bowel disease . Some of us (Gri et al., 2008; Piconese et al., 2009 ) and others (Lu et al., 2006) have demonstrated MC interaction with regulatory T cells (Treg), a well-known T cell subset endowed with immunosuppressive properties, in anaphylaxis, autoimmunity and transplantation tolerance. A bidirectional cross-talk is established between Treg and MCs in mouse colon polyps and human colorectal cancers, with Treg fostering mastocytosis and MCs promoting Treg skewing into IL-17-producing cells favoring inflammation and tumor growth (Gounaris et al., 2009; Blatner et al., 2010) . Treg-MCs partnership recapitulates the complexity of innate-adaptive networks characterizing gut inflammation and represents a novel target for cancer immunotherapy (Colombo and Piconese, 2009) .
Several reports locate MCs at the interface of the tumor-host interaction (Figure 2) . A loop has been described between local inflammation and immunosuppression involving MCs, myeloid-derived suppressor cells (MDSCs) and Treg. MDSCs are a heterogeneous population of immature myeloid cells expanded in tumor-bearing mice and cancer patients, and endowed with immunosuppressive and proangiogenic abilities (Gabrilovich and Nagaraj, 2009 ). MCs induce MDSC recruitment and activation, MDSCs produce IL-17 that indirectly support Treg accumulation and suppressive function, and in turn Treg produce IL-9, a cytokine c-Kit and mast cells in cancer P Pittoni et al with well-known MC-attractant capabilities . We have recently shown IL-6-secreting MCs, Th17 cells and granulocytes populating the microenvironment of angioimmunoblastic T-cell lymphoma and cooperating to promote vessel sprouting, local inflammation and possibly systemic autoimmune manifestations . MCs also bridge humoral immunity and promotion of tumor progression. Indeed, deposition of immune complexes in early neoplastic stroma first activates FcgRs on MCs that subsequently recruit other proinflammatory leukocytes and initiate the angiogenic switch (Andreu et al., 2010) .
Dissecting c-Kit complexity in disease: c-Kit mouse mutants
Experimental models of c-Kit mutations provide compelling evidence of the pleiotropic and nonredundant activities of this receptor in health and disease, and represent invaluable tools to dissect c-Kit tumor-cell-intrinsic and -extrinsic functions in neoplastic transformation.
Loss-of-function mutations
Several mouse strains harboring spontaneous inactivating mutations in the W locus have been identified so far and employed to investigate MC functions. The most widely used c-Kit mutant has been, until recent years, the Kit W/WÀv model (Kitamura et al., 1978) . This strain, on a WBB6F 1 background, harbors two mutated alleles at the W locus: the W mutation, a G to A point mutation at a splicing donor site, ablating a transmembrane c-Kit portion and impeding protein expression on the cell surface (Nocka et al., 1990) ; and the W-v mutation, a C to T point mutation mapping in the kinase domain, resulting in decreased enzymatic activity (Nocka et al., 1990) (Figure 1) . Therefore, Kit W/WÀv mice exhibit severe MC deficiency in many organs (Kitamura et al., 1978) . They also show other c-Kit-related abnormalities, such as defective melanogenesis, sterility, anemia, neutropenia and ICC deficiency, leading to bile reflux and ulcers (reviewed by Grimbaldeston et al., 2005) .
Differently, the Kit WÀsh mutation, first described in 1982 (Lyon and Glenister 1982) , consists of a genetic inversion in the Kit promoter, spanning 3.1 Mb and encompassing 27 known genes. The 3 0 end of this inversion is located upstream the coding region of Andreu et al. (2010) showed that MCs mediate, via FcgR, the link between the elicitation of humoral immune response, the deposition of immunocomplexes at tumor site, the local activation of angiogenesis and the recruitment of tumor-promoting inflammatory cells (violet arrows). We have recently shown that in the microenvironment of angioimmunoblastic T-cell lymphoma, MCs are the primary source of IL-6, colocalize with Th17 cells and correlate with granulocyte infiltration (blue arrows), indicating that MCs may possibly bridge local inflammation and systemic immunity .
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Kit and breaks a positive element that controls c-Kit expression specifically in MCs (Berrozpe et al., 1999) , whereas the 5 0 breakpoint maps within and disrupts the Corin gene (Nigrovic et al., 2008) . Kit WÀsh/WÀsh mice exhibit profound MC deficiency in many organs, impaired melanogenesis and lack of ICCs, but these mice are neither anemic nor sterile (Tono et al., 1992; Grimbaldeston et al., 2005) . These advantageous features, together with the availability on a C57BL/6 genetic background upon backcrossing, have contributed to the widespread use of Kit WÀsh/WÀsh mutants as experimental model of MC deficiency. However, caution should be exercised in interpreting results in these mice, as they show other haematopoietic abnormalities, such as megakaryocytic and myeloid cell expansion, and cardiac aberrancies likely attributable to Corin disruption (Nigrovic et al., 2008) . Recently, two novel transgenic mouse models have been generated that express the recombinase Cre under the control of a MC-specific promoter, such as MC Protease-5 (Scholten et al., 2008) or alpha-Chymase (Musch et al., 2008) promoters, which may be MC ablated if crossed with transgenic animals carrying a Cre-inducible diphtheria toxin receptor. These new mouse models may replace cKit mutants in many MC studies, but Kit W/WÀv and Kit WÀsh/WÀsh mice still represent valuable instruments for the identification of novel MC-unrelated c-Kit functions.
Gain-of-function mutations
Besides spontaneous c-Kit-inactivating mutations, several experimental models have been generated harboring transgenic expression of c-Kit-activating mutants. The D816V Kit allele expressed under the MC-specific chymase gene promoter spontaneously generates SM, similar to the human counterpart (Zappulla et al., 2005) . Three transgenic models, spontaneously developing GIST, have been generated through the insertion of gain-of-function c-Kit mutations: 558delV at exon 11 (Sommer et al., 2003) , K641E at exon 13 (Rubin et al., 2005) and D818Y at exon 17 (Nakai et al., 2008) (Figure 1 ). All these mutants develop ICC hyperplasia in the gastrointestinal tract and GIST-like tumors, mainly in the cecum (Gunawan, 2008) . These models represent accurate reproduction of human GIST, allowing not only the investigation of molecular mechanisms underlying c-Kit-driven tumorigenesis, but also the study of mutant tumor cell susceptibility to different c-Kit inhibitors (Rossi et al., 2006; Ishikawa et al., 2009) and the evaluation of mastocytosis contribution to the progression of different GIST subtypes. Indeed, in 558delV heterozygous mice, GIST development is accompanied by a condition resembling cutaneous mastocytosis (Sommer et al., 2003) , faithfully mimicking a human syndrome in which GIST is associated to the urticaria pigmentosa form of cutaneous mastocytosis (Robson et al., 2004) . Intriguingly, the homozygous K641E mutation determines c-Kit loss-of-function in MCs, germ cells and melanoblasts, recapitulating the phenotype of Kit W/WÀv mutants (Rubin et al., 2005) . Very little is known about the possible role of non-mutated MCs infiltrating GIST tumor masses. Pronounced MC infiltration has been described in myxoid epithelioid GISTs, a subtype characterized by low/negative c-Kit expression, whose tumorigenesis depends instead on Pdgfra mutations (Sakurai et al., 2004) , suggesting that preserved c-Kit function in MCs is a prerequisite for their tumor-promoting activity.
On-target c-Kit inhibition with TKIs
Aberrant TK activation is the hallmark of most cancers. Cancer cells with active TKs have increased proliferative capability and resist to apoptosis, outcompeting normal cells. In this way, though, tumors become physiologically dependent on the uninterrupted activity of a single mutated oncogene for their maintenance. In such tumors, it is often sufficient to block the activity of a single kinase, in order to induce apoptosis, selective growth arrest and/or differentiation of the malignant cells. This phenomenon, called 'oncogene addiction', provides the rationale for molecular-targeted therapy (Weinstein and Joe, 2008) and related drug discovery. c-Kit represents the ideal example of a druggable kinase, whose inhibition has provided a tremendous change in the outcome of c-Kit-dependent neoplasias.
Imatinib
Small molecule TK inhibitors (TKIs) are orally active compounds able to compete with the ATP-binding site of the catalytic domain of oncogenic TKs. The first TKI approved for clinical use was imatinib mesylate (Gleevec, Novartis, Basel, Switzerland) in 2001. Imatinib was originally developed as an inhibitor for Abelson kinase, which is constitutively activated in Philadelphia chromosome-positive chronic myelogenous leukemia, by a chromosomal translocation that gives rise to the breakpoint cluster region-Abelson kinase fusion protein. The introduction of imatinib in chronic myelogenous leukemia therapy resulted in an impressive clinical success, with more than 90% of patients displaying complete hematological responses. Fortuitously, imatinib was found to inhibit c-Kit and PDGFR as well, so when tested as a potential therapy for GISTs, it was found to be effective in the vast majority of patients (Demetri et al., 2002) . Imatinib is now approved as the standard therapy for unresectable or metastatic GIST, and is also prescribed as an adjuvant treatment after surgery in patients with high-risk GIST.
Second generation TKIs
Unfortunately, the inhibitory effect of imatinib is largely dependent on the nature of c-Kit isoform: imatinib is, in fact, a very potent inhibitor of c-Kit mutants in the juxtamembrane domain found in GISTs, whereas c-Kit molecules altered at the level of the catalytic domain, such as D816V mutants typical of mastocytosis, are relatively resistant. Furthermore, the majority of GIST patients, initially showing good response, eventually experience tumor progression, due to the insurgence of novel point mutations in the ATP-binding pocket and c-Kit and mast cells in cancer P Pittoni et al catalytic regions, which confer resistance to imatinib (Liegl et al., 2008) . The most frequent secondary mutation in these patients is the V654A substitution. This critical shortcoming of imatinib prompted the design of novel TKIs with improved selectivity against specific c-Kit mutants for the treatment of resistant forms of GISTs, but also for other diseases associated with c-Kit activation. Sunitinib (Sutent, Pfizer, New York, NY, USA), introduced as an antiangiogenic drug owing to its inhibition of VEGF receptors, proved effective in imatinib-resistant patients with advanced GIST (Demetri et al., 2006) , and is now its second-line approved treatment. Other second generation TKIs, such as nilotinib (Tasigna, Novartis) and sorafenib (Nexavar, Bayer, Leverkusen, Germany), are currently being tested as third-line treatments in patients with imatinib-and sunitinibresistant GISTs. Dasatinib (Sprycel, Bristol-Myers Squibb, New York, NY, USA) , midostaurin (PKC412, Novartis) (Gleixner et al., 2006) and EXEL-0862 (Exelixis, San Francisco, CA, USA) (Pan et al., 2007) have been shown to inhibit D816V mutants, and clinical trials of midostaurin and dasatinib are currently going on in patients with aggressive SM and MC leukemia. In preclinical trials, masitinib (AB Science, Paris, France) proved to be the most specific inhibitor of c-Kit among TKIs (Dubreuil et al., 2009) .
As different TKIs display different selectivity for c-Kit isoforms, a 'personalized' treatment regimen specifically targeting the oncogenic lesion found in the patient is to be hoped for the next future (Pierotti et al., 2010) . More in general, patient stratification and correct drugpatient matching may be decisive for the outcome. The clinical activity of imatinib in melanoma is an emblematic example. Three independent phase II clinical trials performed in the early 2000s failed to show significant responsiveness to imatinib in unselected melanoma patients. Only after the identification of c-Kit mutations in some melanoma subtypes, researchers were encouraged to treat these patients with TKIs targeting c-Kit, and impressive responses were observed (Woodman and Davies, 2010) .
Off-target cancer therapy with TKIs
TK activity spans well beyond transformed cells. Both tumor-infiltrating and systemically distributed cells of the immune compartment can activate TK receptors during different phases of their development and effector activities. Therefore, the overall antitumor effects exerted by TKIs may arise concurrently, or even primarily, from the bystander targeting of immune cells (Figure 3) . The relevance of tumor-cell-extrinsic targets for imatinib is supported by the observations that GISTs not mutated in Kit or Pdgfra can exhibit (Yang et al., 2008) , MDSCs (Ko et al., 2009) and DCs (Borg et al., 2004) , molecules in the T-cell receptor (TCR) proximal signaling mediate TKI response in Treg (Larmonier et al., 2008) . TKI resistance, confined to the tumor microenvironment, can be induced in MDSCs by the GM-CSF-R pathway (Ko et al., 2010) .
c-Kit and mast cells in cancer P Pittoni et al objective clinical responses to imatinib treatment and that several mouse tumor cell lines are sensitive to the antiproliferative effect of imatinib only in vivo but not in vitro (Borg et al., 2004) . Several possible off-target cells have been described for imatinib and other inhibitors in cancer treatment, even though in many cases it remains difficult to distinguish 1) the contribution of tumor-cell-intrinsic and -extrinsic responses in the overall efficacy, and 2) the specific TK (c-Kit, PDGFR, Abelson kinase, FMS-like TK 3, LCK, MAPK and others) whose blockade is functionally relevant for the final outcome. From a translational point of view, tumor-infiltrating immune cells represent ideal bystander targets for TKIs, being less susceptible than tumor cells to the acquisition of secondary mutations conferring drug resistance. MCs are the prototypical off-target cells for imatinib therapy in cancer, due to their constitutively high expression of c-Kit, strong reliance on c-Kit signal for development and activation, and aforementioned tumor-promoting activities (Galinsky and Nechushtan, 2008) . In a rat transplantable model of prostate cancer driven by MC peritumoral accumulation, treatment with imatinib eradicates MCs and hampers angiogenesis . Imatinib may act as a doubleedged sword in tumors associated with both MC infiltration and tumor-cell-intrinsic activation of TK receptors. For instance, in mice spontaneously developing neurofibromas, imatinib administration reduces tumor growth, promoting apoptosis and decreasing proliferation of tumor cells on the one side, and leading to MC ablation on the other side (Yang et al., 2008) . Similarly, in a pediatric patient with a plexiform neurofibroma, imatinib produced the fast contraction of the tumor mass (Yang et al., 2008) . It is conceivable that both tumor cells and MCs represent therapeutically relevant cell targets of imatinib in this context. Among other disease settings, MCs may also prove relevant as off-targets of c-Kit inhibition strategies in lymphoid malignancies, such as classical Hodgkin's lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia and follicular lymphoma. In these neoplasms, infiltrating MCs have been demonstrated to support clone survival and proliferation, and to negatively affect prognosis (Molin et al., 2002; Tournilhac et al., 2006; Taskinen et al., 2008) .
Besides MCs, other cells of the myelomonocytic lineage, such as MDSCs, can be targeted by TKIs. Sunitinib administration to tumor-bearing mice (OzaoChoy et al., 2009) or to renal cell carcinoma patients (Ko et al., 2009) leads to MDSC decline and elicits an antitumor immune response. Of note, MDSCs accumulate to a lower extent in tumor-bearing Kit W/WÀv mice and fail to respond to sunitinib treatment, suggesting a crucial role for c-Kit, rather than other TKs, in MDSC expansion (Ko et al., 2009) . Resistance to sunitinib has been reported in tumor-infiltrating, compared with splenic, MDSCs via the GM-CSF/STAT5-pathway, suggesting that compartmentalized MDSC unresponsiveness to TKIs may be overcome by concurrently targeting such signal (Ko et al., 2010) .
Dendritic cells (DCs) can express c-Kit and produce SCF in some circumstances, thus autonomously sustaining IL-6 production and Jagged-2 expression that are necessary for the arrangement of optimal Th2 and Th17 responses in allergic asthma (Krishnamoorthy et al., 2008) . The successful cross-talk between DCs and natural killer cells may result in a productive cytotoxic attack to tumor cells. The Zitvogel's group has demonstrated that long-term exposure to imatinib enhances the natural killer-stimulatory ability of DCs ex vivo and in vivo, in mice and GIST patients (Borg et al., 2004) , and that natural killer activation is an independent prognostic factor of survival in advanced GISTs treated with imatinib (Menard et al., 2009) . The observation that Kit W/WÀv DCs functionally phenocopy imatinib-treated DCs indicates c-Kit as the relevant imatinib target in DCs (Borg et al., 2004) . Combined administration of imatinib and IL-2 to tumor-bearing mice results in the expansion of a novel DC subset, named interferon-producing killer DCs, specialized in interferon-g secretion and endowed with a TRAILdependent tumor-cell-killing ability (Taieb et al., 2006) .
The stimulation of the T-cell receptor or costimulatory molecules on T-cell surface initiates a phosphorylation cascade that is sensitive to TKIs; therefore, the potential antitumor efficacy of these drugs may be constrained by the impaired development of an adaptive tumor-specific response. Direct inhibitory effects of TKIs on T-cell activation have been reported, which should be kept into account when designing anticancer therapeutic strategies, such to maximize antitumor response and avoid opportunistic infections (Dietz et al., 2004; Seggewiss et al., 2005) . Blockade of T-cell activation becomes beneficial in cancer immunotherapy when the targeted cells are immunomodulatory cells that favor tumor progression, such as Treg. Imatinib has been reported to decrease Treg-suppressive function in vitro and in vivo, an effect mostly due to the inhibited phosphorylation of ZAP70 and LAT molecules following T-cell receptor stimulation Larmonier et al., 2008) .
Conclusions
The beneficial effects produced by c-Kit inhibition in tumors whose clone expansion is supported by mutated ligand-independent c-Kit kinase are beyond question. A similar efficacy may be envisaged for TKIs against stemlike subpopulations of cancer cells expressing nonmutated c-Kit. TKIs have low specificity, but this apparent limit turns into the advantage of hitting bystander cells needed for tumor progression. Among them, MCs represent the ideal off-target, in light of the plentitude of functions they play in several tumor settings and of their strong reliance upon c-Kit signaling. In turn, TKIs should be the treatment of election when MC depletion or blockade is pursued as anticancer therapy. In fact, non-c-Kit-directed strategies could lead to unpredictable outcomes because MCs may c-Kit and mast cells in cancer P Pittoni et al arrange cell interactions yet to be identified. An intriguing possibility is that they may exert homeostatic control on SCF-dependent stem-like cancer cells, for instance by regulating the local availability of SCF in the tumor microenvironment, acting as decoy cells that sequester the common SCF ligand.
In conclusion, we hope that in the future, oncologic patients will benefit from a personalized therapy tailored to target not only the specific TK and its specific genetic lesion, but also the specific off-target, relevant for tumor progression in each single case.
